Gastroenterology Impact Factor

The first signal is status. Gastroenterology is operating at the top of the GI market, not in the large middle tier of solid specialty journals.

The second signal is durability. The five-year JIF of 26.9 is actually higher than the current JIF. That usually points to a journal whose strongest papers retain value beyond a short citation spike.

The third signal is quality after normalization. The JCI of 5.48 is extremely strong. That matters because gastroenterology and hepatology have very different citation cultures across endoscopy, liver disease, IBD, microbiome work, and translational basic science. A JCI at this level means the journal is outperforming category baseline by a wide margin.

The JIF without self-cites is 24.5, which is close to the headline JIF. That is a useful trust signal. The number is not being materially propped up by self-referential citation behavior.

The JCR row above is the authoritative impact factor on this page. For the longer directional view, the table below uses the open Scopus-based impact score series as a trend proxy.

Directionally, the open citation signal is down from 7.65 in 2023 to 7.19 in 2024, and well below the 2021 to 2022 peak. That is the same broad normalization pattern visible across many clinical and translational biomedical journals after the unusual citation cycle of the early 2020s.

The healthier read is that Gastroenterology remains an elite GI title even after that normalization. The drop is not a loss of journal identity. It is a reversion from an inflated citation environment.

The common mistake is to read a very high impact factor and assume the journal mainly rewards prestige or brand.

That is not how Gastroenterology usually works in practice. The journal is still screening for:

• broad GI or hepatology consequence
• strong translational or clinical relevance
• a first-page significance case that feels flagship-ready
• a package that can hold both clinician and investigator attention

That means a very good local paper can still be the wrong fit. The metric tells you where the journal sits. It does not tell you that the paper belongs there.

In our pre-submission review work on manuscripts targeting Gastroenterology, the repeat problem is not a weak dataset. It is a weak significance case.

The paper may be technically strong, but the first page still reads like a good GI paper rather than a flagship GI paper.

In our pre-submission review work on manuscripts targeting Gastroenterology, four failure patterns recur.

The study is too narrow. A well-run single-center or limited-cohort paper can still fail here if the consequence does not travel beyond that context.

The translational bridge is incomplete. Mechanistic work without convincing human relevance often reads one step short of the journal's editorial bar.

The clinical paper is useful, not field-moving. That is often enough for a good journal, but not enough for this one.

The title and abstract undersell the consequence. At this level, the editor should not have to dig for the reason the paper matters.

If that sounds like the package, a Gastroenterology submission readiness check is usually more useful than another round of cosmetic revision.

The impact factor does not tell you whether the manuscript is broad enough, whether the translational bridge is convincing enough, or whether the better owner is Gut, CGH, Hepatology, or a narrower specialty title.

That is where the metric becomes misleading. It describes the journal. It does not validate the fit.